← Evidence map

TrialOpen forum infectious diseases2026

Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial.

Hilda Angela Mujuru et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial. | OpenQuestion